Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade

Shares of Nuvation Bio Inc. (NYSE:NUVB) gapped down before the market opened on Tuesday after UBS Group lowered their price target on the stock from $10.00 to $7.00. The stock had previously closed at $5.84, but opened at $4.81. UBS Group currently has a neutral rating on the stock. Nuvation Bio shares last traded at $4.3680, with a volume of 2,245,625 shares trading hands.

Several other research analysts also recently commented on NUVB. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a report on Thursday, January 22nd. Citizens Jmp set a $10.00 price target on Nuvation Bio in a research note on Thursday, November 20th. HC Wainwright cut their price target on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, Royal Bank Of Canada lifted their price objective on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Nuvation Bio currently has an average rating of “Moderate Buy” and an average target price of $11.44.

Key Stories Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Nuvation says it is transitioning to a commercial-stage company with progress for Iptrozi (IBTROZI) and safusidenib, signaling revenue-led growth and a commercialization focus that investors prize. Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
• Positive Sentiment: Q4/2025 results showed revenue above consensus ($41.9M vs. $36.8M) and management highlighted strong market acceptance of its marketed oncology product(s) and an expanding partner footprint — supportive for near-term commercial revenue. Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target to $13 and kept an outperform rating, which can boost investor sentiment about upside to commercialization prospects. Benzinga: RBC raises PT to $13
• Positive Sentiment: Management outlined a first‑line growth strategy for IBTROZI with a long median duration of response (~50 months) and expanding global partnerships, reinforcing the product’s commercial potential. Nuvation Bio outlines first-line IBTROZI growth strategy
• Negative Sentiment: A law firm (Johnson Fistel) announced an investigation into potential securities-law claims involving NUVB and its executives, raising governance/legal risk that can pressure the stock if it develops. Johnson Fistel investigation notice
• Negative Sentiment: TipRanks flagged new commercialization and partner-execution risks for taletrectinib, underscoring execution challenges that could limit upside if partnerships or launches underperform. Taletrectinib commercialization risks
• Negative Sentiment: UBS cut its price target from $10 to $7 and placed a neutral rating, a downgrade that may weigh on sentiment even though other analysts remain more bullish. Benzinga: UBS lowers PT to $7

Institutional Investors Weigh In On Nuvation Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NUVB. Rangeley Capital LLC bought a new stake in shares of Nuvation Bio in the 2nd quarter valued at approximately $25,000. Parallel Advisors LLC raised its holdings in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares during the period. Cetera Investment Advisers purchased a new stake in Nuvation Bio during the 2nd quarter valued at $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio in the second quarter worth $32,000. Finally, Swiss Life Asset Management Ltd bought a new stake in Nuvation Bio in the third quarter worth $39,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Nuvation Bio Price Performance

The company has a quick ratio of 8.39, a current ratio of 6.95 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.63 billion, a PE ratio of -7.90 and a beta of 1.50. The firm’s 50 day simple moving average is $6.45 and its 200 day simple moving average is $5.53.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The business had revenue of $41.87 million for the quarter, compared to the consensus estimate of $36.82 million. As a group, research analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.